The Research Supporting BHRT: Key Clinical Evidence
Bioidentical hormone replacement therapy is sometimes portrayed as lacking a rigorous evidence base—a claim that reflects both outdated assumptions and insufficient familiarity with the current literature. In fact, substantial and growing clinical evidence supports the safety, efficacy, and long-term health benefits of bioidentical hormones when used appropriately. Here is an overview of the key studies and trials that inform evidence-based BHRT practice.
The Women's Health Initiative: Misinterpretation and Re-Analysis
No discussion of BHRT research can begin without addressing the Women's Health Initiative (WHI), the 2002 trial whose findings triggered a massive and largely unwarranted retreat from hormone therapy that harmed millions of women. The WHI tested two hormone regimens: conjugated equine estrogens (CEE) alone (for women without a uterus) and CEE combined with medroxyprogesterone acetate (MPA) for women with a uterus. The combined arm was stopped early in 2002 due to a reported increase in breast cancer and cardiovascular events.
What the initial reporting obscured were several critical limitations. The average age of participants was 63—more than a decade past menopause for most—a population very different from the typical candidate for HRT. The oral CEE formulation increases clotting factors through first-pass liver metabolism, a risk that transdermal estradiol does not share. MPA—a synthetic progestin, not bioidentical progesterone—was responsible for the breast cancer signal; the estrogen-only arm actually showed a reduction in breast cancer risk after several years. Subsequent re-analyses of the WHI data have confirmed that younger women (aged 50–59 or within 10 years of menopause) who used estrogen had significantly reduced cardiovascular events, reduced all-cause mortality, and no increase in breast cancer—a pattern called the "healthy timing" or "critical window" effect.
KEEPS: The Kronos Early Estrogen Prevention Study
The KEEPS trial was specifically designed to address the "timing hypothesis"—the question of whether estrogen therapy initiated early in the menopausal transition has different effects than therapy initiated late. KEEPS randomized 727 recently menopausal women (within three years of final menstrual period) to oral conjugated equine estrogens, transdermal estradiol, or placebo for four years.
Key findings: Both estrogen arms significantly reduced menopausal symptoms compared to placebo. The transdermal estradiol arm showed improvement in mood and had a favorable effect on bone mineral density without adverse lipid effects. Neither estrogen formulation showed negative cardiovascular effects in this recently menopausal population—contrasting with the adverse outcomes seen in the older WHI participants. Importantly, the KEEPS Cognition Study showed that women treated with oral CEE performed better on verbal learning tasks, while transdermal estradiol improved visual memory—supporting the neuroprotective potential of early estrogen therapy.
ELITE: Early vs. Late Intervention Trial with Estradiol
The ELITE trial directly compared cardiovascular outcomes in recently menopausal women (within six years of menopause) versus late postmenopausal women (more than 10 years past menopause) treated with oral estradiol. The results strikingly confirmed the critical window hypothesis: women who began estradiol therapy early showed significantly less progression of carotid intima-media thickness (CIMT, a marker of atherosclerosis) compared to placebo, while women who began therapy late showed no benefit and a non-significant trend toward harm.
ELITE provides compelling evidence that estradiol therapy, when initiated close to the menopausal transition, has cardioprotective effects—and that timing matters enormously. This finding supports initiating estrogen therapy at the onset of menopausal symptoms rather than waiting years until symptoms have significantly progressed.
The E3N Cohort: Bioidentical Hormones and Breast Cancer Risk
The E3N (Etude Epidémiologique auprès des femmes de la Mutuelle Générale de l'Education Nationale) cohort is a landmark French prospective study that followed more than 80,000 postmenopausal women for over a decade and directly compared the breast cancer risk of different hormone preparations. The findings were unambiguous: women using estrogen combined with synthetic progestins (particularly MPA) had significantly increased breast cancer risk (relative risk approximately 1.4), while women using estrogen combined with natural (bioidentical) progesterone had no increased breast cancer risk.
These findings have been replicated in multiple independent cohort studies and meta-analyses, establishing bioidentical progesterone as the safe choice for endometrial protection in women using estrogen therapy—and challenging the assumption that all progestogens carry the same risk profile.
Testosterone Pellet Research
Subcutaneous testosterone pellet therapy has been studied in both men and women with consistent findings. In women, pellet-dosed testosterone has been associated with improved libido, energy, mood, bone density, and breast cancer risk reduction in several observational studies. A widely cited analysis by Glaser and Dimitrakakis found that testosterone pellet therapy was associated with a significant reduction in breast cancer incidence in women receiving concomitant BHRT—a finding that, while observational, suggests testosterone may have protective breast effects.
In men, testosterone pellet therapy has been associated with sustained normalization of testosterone levels, improved body composition, reduced cardiovascular risk markers, and improved sexual function. Studies consistently show that pellet delivery maintains more stable serum levels than injection or topical formulations, potentially reducing symptom fluctuations between doses.
TRT and Cardiovascular Safety: The TRAVERSE Trial
The TRAVERSE trial (2023), a large randomized controlled trial of testosterone replacement in men with hypogonadism and elevated cardiovascular risk, found that testosterone therapy did not increase—and in some secondary endpoints reduced—the risk of major adverse cardiovascular events compared to placebo. This trial, the largest cardiovascular outcome trial of TRT ever conducted, significantly strengthened the evidence supporting testosterone therapy for symptomatic hypogonadal men.
GLP-1 Research: SELECT and SURMOUNT Trials
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in overweight and obese adults with established cardiovascular disease—making it one of the most significant cardiovascular outcome trials of the past decade. The SURMOUNT-1 trial demonstrated average weight loss of 20–22% with tirzepatide over 72 weeks—the largest average weight loss ever demonstrated with a pharmacological agent.
Evidence-Based BHRT Practice
The evidence base for bioidentical hormone therapy is substantial, nuanced, and increasingly robust. Applying it correctly requires understanding the distinctions between bioidentical and synthetic hormones, the critical window of timing, the importance of delivery route, and the individualized nature of hormonal needs. Kenton Bruice, M.D., practices evidence-based hormone medicine at his clinics in Denver, Aspen, and St. Louis—integrating the latest research into personalized treatment protocols. Schedule a consultation with Dr. Bruice to discuss how the evidence applies to your specific situation.